CSI Market
Sign In | Register

Esperion Therapeutics Inc (ESPR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ESPR Annual Cash Flow →
Quarterly cash flow trends provide additional context on Esperion Therapeutics Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-25.20
Depreciation & amortization0.03
Amortization of Other Assets0.59
Increase (Decrease) in Deferred Revenue9.05
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.92
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Other Assets0.00
Share-based Compensation2.50
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Amortization Of Debt Discount Premium And Beneficial Conversion-
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Non Cash Royalty Revenue Related To Sale Of Future Royalties-18.48
Non Cash Interest Expense Related To Revenue Interest Liability-
Non Cash Interest Expense Related To Royalty Sale Liability13.89
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable7.84
Increase (Decrease) in Accounts Payable3.34
Increase (Decrease) in Other Accrued Liabilities-4.86
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-17.34
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-27.72
Investing Activities
Capital Expenditures-0.19
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire In Process Research And Development Other Than Through Business Combination-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.19
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock16.22
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-167.88
Proceeds From Issuance Of Preferred Stock And Preference Stock Net Of Issuance Costs-
Proceeds From Issuance Of Warrants Fair Value Estimate-
Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs-
Payments From Revenue Interest Purchase Agreement-
Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Issuance Of Common Stock From A T M Program-
Proceeds From Pre Funded Warrant Exercises-
Proceeds From Royalty Sale Liability Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents167.85
Common Stock Issuance Costs Incurred Not Yet Paid-
Capital Expenditures Incurred But Not Yet Paid-
Non Cash Right Of Use Asset0.03
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities16.22
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-27.91
Total Cash Flow-11.69
4 historic quarters locked

Sign in to unlock the full Esperion Therapeutics Inc cash flow history.

Sign In Create Free Account

About Esperion Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-032870

Figures are derived from filed reports and may be restated. Historical data is subject to revision.